MGNX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MGNX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Macrogenics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $152.61 Mil. Macrogenics's Total Assets for the quarter that ended in Dec. 2023 was $298.42 Mil. Therefore, Macrogenics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.51.
The historical rank and industry rank for Macrogenics's Equity-to-Asset or its related term are showing as below:
During the past 13 years, the highest Equity to Asset Ratio of Macrogenics was 0.87. The lowest was 0.51. And the median was 0.73.
The historical data trend for Macrogenics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Macrogenics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Equity-to-Asset | Get a 7-Day Free Trial | 0.74 | 0.78 | 0.72 | 0.51 | 0.51 |
Macrogenics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Equity-to-Asset | Get a 7-Day Free Trial | 0.51 | 0.32 | 0.56 | 0.57 | 0.51 |
For the Biotechnology subindustry, Macrogenics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Macrogenics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Macrogenics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Macrogenics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Equity to Asset (A: Dec. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 152.613 | / | 298.418 | |
= | 0.51 |
Macrogenics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as
Equity to Asset (Q: Dec. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 152.613 | / | 298.418 | |
= | 0.51 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Macrogenics (NAS:MGNX) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Macrogenics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Ezio Bonvini | officer: Sr VP, Research & CSO | 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
Biotech Target N V | 10 percent owner | ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000 |
Edward Hurwitz | director | |
Jeffrey Stuart Peters | officer: Acting General Counsel | 9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
Margaret Liu | director | C/O SANGAMO, POINT RICHMOND TECH CNTR II, 501 CANAL BLVD, SUITE A-100, RICHMOND CA 94804 |
Meenu Chhabra | director | C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103 |
James Karrels | officer: SVP, CFO and Secretary | 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
William K Heiden | director | C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451 |
Thomas Spitznagel | officer: Sr VP, BPD & Manufacturing | 9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
Biotech Ag Bb | 10 percent owner | SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200 |
Federica F. O'brien | director | C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355 |
Eric Blasius Risser | officer: Sr VP & Chief Business Officer | 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
Kenneth Galbraith | director | OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1 |
Stephen L. Eck | officer: Chief Medical Officer | 12212 TECHNOLOGY BLVD., AUSTIN TX 78727 |
Matthew K Fust | director | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
From GuruFocus
By Value_Insider Value_Insider • 11-03-2022
By Marketwired • 10-31-2023
By sperokesalga sperokesalga • 03-02-2023
By Marketwired • 09-05-2023
By sperokesalga sperokesalga • 04-24-2023
By Value_Insider Value_Insider • 10-26-2022
By GlobeNewswire GlobeNewswire • 07-08-2022
By sperokesalga sperokesalga • 02-13-2023
By GuruFocus Research • 11-06-2023
By Marketwired • 11-02-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.